Combining the irreversible pan-ErbB inhibitor pyrotinib with capecitabine reduced the risk of disease progression or death by 64% compared with lapatinib (Tykerb) plus capecitabine in Chinese patients with relapsed or metastatic HER2-positive breast cancer who previously received taxanes, anthracyclines, and/or trastuzumab (Herceptin), according to data from a phase II study published in the Journal of Clinical Oncology
Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study (published online August 20, 2019). J Clin Oncol. doi: 10.1200/JCO.19.00108.
... to read the full story